Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harry Sukumaran

Pain Medicine Rochester Hills, MI Medical Doctor

NPI 1356546709 CMS profile 288904

2820 Crooks Rd Ste 100, Rochester Hills, MI 48309

Open in the dashboard

General payments

$303,742

767 records reported · program years 2019–2025

Research payments

$268

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,720 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Harry Sukumaran of Rochester Hills, MI is reported in the CMS Open Payments database as having received $303,742 across 767 general payments and $268 in research payments paid to them. Separately, studies naming them as principal investigator received $4,720 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54,077 100
2024 General $53,628 122
2023 General $47,845 110
2022 General $47,417 119
2021 General $51,642 122
2021 Research $13 1
2020 General $30,437 72
2019 General $18,694 122
2019 Research $255 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harry Sukumaran
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Harry Sukumaran were reported at $54,077. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Harry Sukumaran Pain Medicine median Middle half National median
2019 $18,694 $498 $126–$1,682 $163
2020 $30,437 $284 $80–$910 $114
2021 $51,642 $399 $112–$1,219 $132
2022 $47,417 $455 $137–$1,484 $149
2023 $47,845 $484 $128–$1,495 $160
2024 $53,628 $498 $131–$1,540 $164
2025 $54,077 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vertos Medical, Inc. $106,874 151 payments
  2. SPR Therapeutics, Inc $70,916 85 payments
  3. Stryker Corporation $30,778 31 payments
  4. Boston Scientific Corporation $30,315 58 payments
  5. Medtronic, Inc. $16,870 68 payments
  6. SI-BONE, Inc. $15,504 23 payments
  7. Nevro Corp. $11,800 63 payments
  8. Abbott Laboratories $4,770 62 payments
  9. NeuroOne Medical Technologies Corporation $4,431 4 payments
  10. Spinal Simplicity, LLC $2,453 29 payments
  11. Other $9,032 193 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $185,928 79 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45,850 12 payments
  3. Travel and Lodging $34,413 77 payments
  4. Food and Beverage $32,636 595 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $3,410 3 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,505 1 payment
Products named General payments · program years 2019–2025
  1. mild Device Kit Orthopedic $73,602 109 payments
  2. SPRINT PNS System $70,416 84 payments
  3. mild Device Kit Orthopedic $33,272 42 payments
  4. MILD DEVICE KIT Instruments $23,136 12 payments
  5. MILD DEVICE KIT Instruments $15,678 14 payments
  6. INTELLIS ADAPTIVESTIM $15,384 38 payments
  7. IFUSE IMPLANT SYSTEM $15,071 14 payments
  8. Superion $11,763 13 payments
  9. Superion Indirect Decompression System $10,210 17 payments
  10. Omnia $9,840 31 payments
  11. Other $33,929 408 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $268 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

346

Median for Pain Management: 951

Drug cost

$7,548

Median for Pain Management: $26,034

Branded share of claims

45.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 14 $3,652
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 97 $1,669
Gabapentin Generic 53 $660
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 49 $615
Pregabalin Generic 19 $259
Oxycodone Hcl Generic 18 $202
Morphine Sulfate Er Morphine Sulfate Brand 12 $165
Duloxetine Hcl Generic 13 $115
Tramadol Hcl Generic 31 $78
Nortriptyline Hcl Generic 11 $54

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$137,900

Medicare's payments for the services billed

Medicare patients

195

Average age 73

Services billed

944

114 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Diabetes 35%
Ischemic heart disease 33%
Chronic kidney disease 28%
Depression 26%
COPD 24%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
$43 — —
RELISTOR
$29 — —
Qutenza
$20 — —
XTAMPZA
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

770 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record